On the basis of the aforementioned findings, several molecules targeting the kinase activity of FAK or its kinase-independent scaffold functions have been shown to elicit anticancer effects in preclinical tumor models, including breast cancer [27,28,29,30]. The gene discussed is PTK2; the disease is breast carcinoma.